Diagnostic potential of circulating natriuretic peptides in chronic kidney disease.
暂无分享,去创建一个
R. Gansevoort | A. Jardine | T. McDonagh | P. Mark | H. Dargie | R. Rodger | C. Petrie | G. Stewart
[1] Pedro Lozano. Natriuretic peptides. , 2020, The Journal of the Arkansas Medical Society.
[2] R. Christenson,et al. N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[3] Charles E McCulloch,et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.
[4] Satoko Nakamura,et al. Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[5] A. Voors,et al. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. , 2004, Journal of the American College of Cardiology.
[6] P. Armstrong,et al. Renal Insufficiency and Heart Failure: Prognostic and Therapeutic Implications From a Prospective Cohort Study , 2004, Circulation.
[7] J. Hollander,et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[8] S. Reis,et al. Mild Renal Insufficiency Is Associated With Angiographic Coronary Artery Disease in Women , 2002, Circulation.
[9] C. Zoccali,et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. , 2001, Journal of the American Society of Nephrology : JASN.
[10] C. Zoccali,et al. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. , 2001, Kidney international.
[11] Colin Baigent,et al. Premature cardiovascular disease in chronic renal failure , 2000, The Lancet.
[12] C. Frampton,et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.
[13] H. Tunstall-Pedoe,et al. Biochemical detection of left-ventricular systolic dysfunction , 1998, The Lancet.
[14] P. Poole‐Wilson,et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care , 1997, The Lancet.
[15] Kazuhiro Takahashi,et al. Urinary immunoreactive brain natriuretic peptide in patients with renal disease , 1996, Regulatory Peptides.
[16] David C. Murray,et al. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. , 1995, Journal of the American Society of Nephrology : JASN.
[17] A. Jardine,et al. Pulmonary extraction and left atrial secretion of atrial natriuretic factor during cardiopulmonary bypass surgery. , 1992, American heart journal.
[18] I. Tikkanen,et al. Plasma level of atrial natriuretic peptide as an indicator of increased cardiac load in uremic patients. , 1990, Clinical nephrology.
[19] A. DeMaria,et al. Recommendations Regarding Quantitation in M-Mode Echocardiography: Results of a Survey of Echocardiographic Measurements , 1978, Circulation.
[20] R. Gansevoort,et al. Electrocardiographic abnormalities and uremic cardiomyopathy. , 2005, Kidney international.